Cancer Screenings by Age: A Practical Overview

What is cancer screening — and what it is not

Screening means testing people who have no symptoms to find cancer or pre-cancer early, when it is most treatable. It is different from a diagnostic test, which is ordered because there is already a symptom or concern. If you have a symptom — an unexplained lump, blood where it should not be, rapid unexplained weight loss — you need a diagnostic evaluation promptly. Do not wait for a scheduled screening appointment if something already concerns you.

Cervical cancer screening: who, when, and how often

Who: People with a cervix.

When to start: Age 21, regardless of sexual history.

Schedule per USPSTF guidance 1Ref 1US Preventive Services Task Force (2018).Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.Cervical cancer screening schedule: Pap at 21, co-testing options ages 30–65, criteria for stopping after 65: - Ages 21–29: Pap smear alone every 3 years - Ages 30–65: Pap + HPV co-test every 5 years, OR Pap alone every 3 years, OR HPV test alone every 5 years - After 65: screening may stop with adequate prior normal results - After total hysterectomy (cervix removed) for a non-cancerous reason: routine screening is generally not needed

Higher-risk groups (HIV, immunosuppression, prior high-grade abnormal results) need more frequent screening — your clinician sets the schedule.

Colorectal cancer screening: when to start and which test to choose

Who: All adults.

When to start: Age 45 for average-risk adults per the American Cancer Society recommendation and current USPSTF guidance 2Ref 2Davidson KW, Barry MJ, Mangione CM, et al. (US Preventive Services Task Force) (2021).Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.Colorectal cancer screening for average-risk adults starting at age 45, with multiple acceptable modalities. Some prior guidelines said 50 — both ages appear in clinical practice; 45 is now the primary recommendation from most major bodies.

Options: - Colonoscopy every 10 years — the most comprehensive option; finds and removes precancerous polyps in one procedure 3Ref 3National Institute of Diabetes and Digestive and Kidney Diseases (2023).Colonoscopy.Colonoscopy as the most comprehensive colorectal screening option that finds and removes polyps in one procedure - Annual fecal immunochemical test (FIT) or fecal occult blood test (FOBT) - Stool DNA test every 1–3 years - CT colonography (virtual colonoscopy) every 5 years

The ACG colorectal cancer screening guideline affirms multiple acceptable options and recommends shared decision-making about which fits best 4Ref 4Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK (2021).ACG Clinical Guidelines: Colorectal Cancer Screening 2021.ACG guideline affirming multiple acceptable colorectal screening options and shared decision-making about modality.

Start earlier (age 40 or 10 years before the youngest affected family member) if: a first-degree relative had colorectal cancer or advanced polyps — especially before 60; or you have inflammatory bowel disease; or certain genetic syndromes.

When to stop: Generally around age 75 for average-risk adults, with individualized discussion for ages 76–85.

Breast cancer screening: navigating the guideline variation

Who: People with breasts (primarily women).

When to start: This is an area of active guideline variation. - The USPSTF (2024) recommends biennial mammography starting at age 40 5Ref 5Nicholson WK, Silverstein M, Wong JB, et al. (US Preventive Services Task Force) (2024).Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement.USPSTF 2024 recommendation for biennial mammography starting at age 40 - The American Cancer Society recommends offering annual mammograms from age 40, with a strong recommendation to start no later than 45 - Most guidelines support continuing screening until at least age 74

Start earlier or screen more intensively if: A first-degree relative had breast cancer (especially pre-menopausal), BRCA1/2 mutation is present, prior breast biopsy showed high-risk cells, you have dense breasts, or you had prior chest radiation.

Dense breasts: Mammography is less sensitive in dense breast tissue. Some states require notification, and supplemental screening (ultrasound or MRI) may be offered.

Lung cancer screening: who qualifies and what the test involves

Who: Adults ages 50–80 with a significant smoking history — currently defined as a 20 pack-year history (one pack per day for 20 years, or two packs for 10 years) who currently smoke or quit within the past 15 years 6Ref 6Krist AH, Davidson KW, Mangione CM, et al. (US Preventive Services Task Force) (2021).Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.Annual low-dose CT for lung cancer screening in adults ages 50–80 with a 20 pack-year smoking history who currently smoke or quit within 15 years.

Test: Annual low-dose CT (LDCT) of the chest.

Important: This screening has genuine benefit for high-risk smokers but would cause net harm in the general population because of false positives and follow-up procedures. If you smoke but are not sure whether you meet the criteria, ask your clinician.

Prostate cancer screening: a shared decision, not a uniform recommendation

Who: Men and people with a prostate.

When to start the conversation: - Age 50 for average-risk men per USPSTF guidance 7Ref 7US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Prostate cancer screening as a shared decision for men ages 55–69; USPSTF framework for PSA discussion - Age 40–45 for Black men (who have higher incidence) and men with a first-degree relative who had prostate cancer before 65, per the AUA/SUO guideline 8Ref 8Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.AUA/SUO guideline recommending earlier PSA discussion (ages 40–45) for Black men and men with first-degree family history

The nuance: Unlike other screenings, prostate screening is a shared decision between you and your clinician — not a flat universal recommendation. The PSA test has a significant false-positive rate, and some prostate cancers found by screening would never cause harm in a person's lifetime. The conversation weighs potential benefit of early detection against risk of over-diagnosis and over-treatment.

Skin cancer: what to watch and when to see a dermatologist

The USPSTF concludes that the evidence is insufficient to recommend routine full-body skin exams by a clinician in average-risk adults 9Ref 9US Preventive Services Task Force (2023).Skin Cancer: Screening (Final Recommendation Statement).USPSTF finding of insufficient evidence to recommend routine clinician skin cancer screening for average-risk adults. However, self-examination is worthwhile. The ABCDE rule for melanoma detection helps identify concerning lesions: Asymmetry, Border irregularity, Color variation, Diameter larger than a pencil eraser, Evolution or change over time 10Ref 10AAD Ad Hoc Task Force for the ABCDEs of Melanoma; Tsao H, Olazagasti JM, Cordoro KM, et al. (2015).Early detection of melanoma: reviewing the ABCDEs.ABCDE criteria for self-examination and early melanoma detection.

See a dermatologist if you notice a changing or unusual lesion. Higher-risk individuals — fair skin, many moles, prior skin cancer, extensive sun or tanning bed exposure, family history of melanoma — should discuss regular professional skin exams with a clinician.

Tests not recommended for average-risk adults

Several tests are commonly requested but not recommended as routine screening for average-risk people: whole-body MRI, CT full-body scans, general tumor marker blood tests (CA-125 or CEA without a specific indication), and routine chest X-rays for lung cancer. These carry real risks of false positives, unnecessary follow-up procedures, and radiation exposure. More testing is not always better.